NCT04610801

Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2

A Randomized Placebo Control Trial to Evaluate the Efficacy of Xylitol Nasal Spray vs. Placebo for Acute COVID-19 Infection

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Larkin Community Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to assess the efficacy of Xylitol plus Grapefruit Seed Extract (Xlear) nasal spray as an adjunct treatment of COVID-19.

Detailed description

After being informed about the study and potential risk, all patients giving written informed consent will undergo a brief screening period to determine eligibility for the study. Once eligibility is confirmed, patients who meet the eligibility requirements will be randomized placebo control manner. Patient will be assigned to Xlear (2 puffs per nosetrils, every 3-4 hours a day) or placebo. Patient will be followed for 1 week. Inflammatory markers will be obtained on Day 4 and repeat COVID-19 RT PCR on Day 7. Follow up will be done on Day 14 for all patients.

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	Nasal Spray	Randomized to placebo and Xlear

Timeline

• Start date: 2021-12-08
• Primary completion: 2022-06-08
• Completion: 2022-08-08
• First posted: 2020-11-02
• Last updated: 2023-10-16

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study